Since its creation in 2000, Gavi and its partners have made significant strides in delivering cost-effective vaccines around the world. Yet, a rapidly changing global landscape—marked by rapid urbanization, increasing vaccine hesitancy, and protracted displacement—is impeding global vaccination efforts. Immunization coverage rates remain highly variable, and in some cases far below levels required for sustained public health impact.
The COVID-19 pandemic further exacerbated these challenges, leading to historic backsliding on routine immunization and a resurgence in vaccine-preventable diseases. Current macroeconomic conditions are constraining foreign aid budgets and squeezing health care budgets in low- and middle-income countries, alike.
While Gavi’s mission—to save lives and protect people's health by increasing equitable and sustainable use of vaccines—remains highly relevant, there is also a need to continue to adapt its model to deliver health impact and value for money.
Against this backdrop, CGD is undertaking a program of work to inform Gavi’s board and leadership, as well as the broader immunization and global health communities, in the lead up to its next strategic period (2026-2030), known as “Gavi 6.0”. Leveraging CGD’s expertise in technical areas such as cost-effectiveness, value for money, and procurement, alongside extensive knowledge of the global health and broader development finance landscapes, CGD will produce timely analysis on priorities and policy options to sustain and enhance Gavi’s impact going forward. CGD will build on a long track record of providing research on Gavi-related issues, which most recently included an extensive analysis conducted in 2019-2020 to inform Gavi’s 5.0 strategy.
